Key result
Among 912 patients treated with TAVR, the incidence of coronary access at a median follow-up of 769 days was 5.3%, and percutaneous coronary intervention was successful in all but one case.
Why the study?
The long-term incidence of coronary access after TAVR was unknown, and coronary access and PCI after TAVR may present technical challenges, especially with supra-annular devices.
What is the incidence and feasibility of coronary access after transcatheter aortic valve replacement?
Cohort (n=912)
No
What is the incidence and feasibility of coronary access after transcatheter aortic valve replacement?
Coronary access after TAVR is infrequent (5.3%) but generally feasible and safe, though supra-annular devices may present challenges for right coronary artery engagement.
Answers are grounded in this paper and cite their sources.
Reassures on post-TAVR coronary access feasibility in real-world cohorts; leaves open device-specific optimization for prospective study.
BACKGROUND: Incidence of coronary access (CA) after transcatheter aortic valve replacement (TAVR) at long-term follow-up remains unknown. CA and percutaneous coronary intervention (PCI) after TAVR might present technical challenges, particularly with supra-annular devices. METHODS: Patients undergoing CA after being treated with TAVR at our institution were included in the study. Coronary interventions for coronary obstruction during TAVR procedure were excluded. Incidence, feasibility and outcomes of CA after TAVR were analyzed. RESULTS: Out of 912 patients aged 80 ± 7 years treated with TAVR at our institution between 2007 and 2018, 48 (5.3%) underwent CA at a median follow up of 769 [363-1,471] days. Twenty-one had received a SAPIEN XT, 15 a SAPIEN 3, 6 Corevalve, 2 Evolut Pro, 2 JenaValve, and 2 Lotus valve. PCI was indicated in 26 (54%) cases. Seventeen (35%) procedures were performed for acute coronary syndromes (ACS). Independent predictors of CA after TAVR were younger age, previous PCI, and CABG. CA of both vessels was feasible in all patients with an intra-annular device, while the right coronary artery was not engaged in two patients with a supra-annular valve. PCI was successful in all but one case. All-cause mortality was similar between patients needing CA for ACS and those who had other clinical indications. CONCLUSIONS: In this high-risk AS population, incidence of CA after TAVR at long-term follow-up was rather low. CA and PCI were safe and successful in most cases, with a lower rate of selective CA for supra-annular devices.
No takes yet. Share an insight, caveat, or question.
Fovino et al. (2020) conducted a cohort in Aortic stenosis (n=912). Transcatheter aortic valve replacement (TAVR) was evaluated on Incidence of coronary access after TAVR. Among 912 patients treated with TAVR, the incidence of coronary access at a median follow-up of 769 days was 5.3%, and percutaneous coronary intervention was successful in all but one case.
Synapse has enriched 10 related papers. Consider them for comparative context: